Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Robert J Motzer et al. J Natl Compr Canc Netw. 2017 Jun.

Abstract

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These guidelines are developed by a multidisciplinary panel of leading experts from NCCN Member Institutions consisting of medical oncologists, hematologists and hematologic oncologists, radiation oncologists, urologists, and pathologists. The NCCN Guidelines are in continuous evolution and are updated annually or sometimes more often, if new high-quality clinical data become available in the interim.

PubMed Disclaimer

Similar articles

  • NCCN Guidelines Updates: Management of Metastatic Kidney Cancer.
    Jonasch E. Jonasch E. J Natl Compr Canc Netw. 2019 May 1;17(5.5):587-589. doi: 10.6004/jnccn.2019.5008. J Natl Compr Canc Netw. 2019. PMID: 31117033
  • NCCN clinical practice guidelines in oncology: kidney cancer.
    Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. Motzer RJ, et al. J Natl Compr Canc Netw. 2009 Jun;7(6):618-30. doi: 10.6004/jnccn.2009.0043. J Natl Compr Canc Netw. 2009. PMID: 19555584 No abstract available.
  • NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
    Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Gunn A, Haas N, Johnson M, Kapur P, King J, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Sweis R, Zibelman M, Schonfeld R, Stein M, Gurski LA. Motzer RJ, et al. J Natl Compr Canc Netw. 2024 Feb;22(1):4-16. doi: 10.6004/jnccn.2024.0008. J Natl Compr Canc Netw. 2024. PMID: 38394781
  • Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012.
    Chiong E, Tay MH, Tan MH, Kumar S, Sim HG, Teh BT, Umbas R, Chau NM. Chiong E, et al. Lancet Oncol. 2012 Nov;13(11):e482-91. doi: 10.1016/S1470-2045(12)70433-3. Lancet Oncol. 2012. PMID: 23117003 Review.
  • Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
    Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, Bhatia S, Budde LE, Chokshi S, Davies M, Elshoury A, Gesthalter Y, Hegde A, Jain M, Kaffenberger BH, Lechner MG, Li T, Marr A, McGettigan S, McPherson J, Medina T, Mohindra NA, Olszanski AJ, Oluwole O, Patel SP, Patil P, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Zaha VG, Lyons M, Dwyer M, Hang L. Thompson JA, et al. J Natl Compr Canc Netw. 2022 Apr;20(4):387-405. doi: 10.6004/jnccn.2022.0020. J Natl Compr Canc Netw. 2022. PMID: 35390769 Review.
See all similar articles

Cited by

See all "Cited by" articles

Publication types